+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

SciSparc Ltd (SPRC) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 44 Pages
  • August 2023
  • GlobalData
  • ID: 5693142
SciSparc Ltd (SPRC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

SciSparc Ltd (SciSparc), formerly Therapix Biosciences Ltd, is a clinical-stage biopharmaceutical company which focuses on the development of cannabinoid-based pharmaceuticals for the treatment of central nervous system disorders. SciSparc's major product candidates include SCI-110, for the treatment of Tourette Syndrome (TS), Obstructive Sleep Apnea (OSA), and Alzheimer's disease and agitation; SCI-210, for the treatment of Autism Spectrum Disorder (ASD) and epilepsy; and SCI-160, for the treatment of pain. The company conducts its clinical programs in collaboration with the various pharma companies and institutions. SciSparc is headquartered in Tel Aviv, Israel.

SciSparc Ltd Key Recent Developments

  • May 30, 2023: SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP
  • May 08, 2023: SciSparc's drug discovery joint venture MitoCareX Bio successfully developed its core algorithm to allow suitable modelling of human mitochondrial carriers for accelerating its cancer drug discovery program
  • Apr 21, 2023: SciSparc and Clearmind collaboration strengthens IP portfolio with Patent application in the U.S. for treatment of depression
  • Feb 22, 2023: Israel-based Clearmind Medicine files patent applications for three unique combinations of future psychedelic-based compounds

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • SciSparc Ltd - Key Facts
  • SciSparc Ltd - Key Employees
  • SciSparc Ltd - Key Employee Biographies
  • SciSparc Ltd - Major Products and Services
  • SciSparc Ltd - History
  • SciSparc Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • SciSparc Ltd - Business Description
  • SciSparc Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • SciSparc Ltd - Strengths
  • SciSparc Ltd - Weaknesses
  • SciSparc Ltd - Opportunities
  • SciSparc Ltd - Threats
  • SciSparc Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • SciSparc Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • SciSparc Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • SciSparc Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 30, 2023: SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP
  • May 08, 2023: SciSparc's drug discovery joint venture MitoCareX Bio successfully developed its core algorithm to allow suitable modelling of human mitochondrial carriers for accelerating its cancer drug discovery program
  • Apr 21, 2023: SciSparc and Clearmind collaboration strengthens IP portfolio with Patent application in the U.S. for treatment of depression
  • Feb 22, 2023: Israel-based Clearmind Medicine files patent applications for three unique combinations of future psychedelic-based compounds
  • Feb 22, 2023: SciSparc and Clearmind reveal three unique combinations of future psychedelic-based compounds
  • Feb 17, 2023: SciSparc's drug discovery joint venture MitoCareX Bio successfully reached first milestone for its future machine learning system
  • Feb 15, 2023: SciSparc and Clearmind collaboration strengthens IP portfolio with three provisional patent applications in the US
  • Feb 15, 2023: Israel-based Clearmind Medicine strengthening IP portfolio with three provisional patent applications in the US
  • Jan 25, 2023: SciSparc announces corporate restructuring plan
  • Nov 08, 2022: SciSparc gains competitive edge with additional U.S. patent granted
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • SciSparc Ltd, Key Facts
  • SciSparc Ltd, Key Employees
  • SciSparc Ltd, Key Employee Biographies
  • SciSparc Ltd, Major Products and Services
  • SciSparc Ltd, History
  • SciSparc Ltd, Subsidiaries
  • SciSparc Ltd, Key Competitors
  • SciSparc Ltd, Ratios based on current share price
  • SciSparc Ltd, Annual Ratios
  • SciSparc Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • SciSparc Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • SciSparc Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • SciSparc Ltd, Performance Chart (2018 - 2022)
  • SciSparc Ltd, Ratio Charts
  • SciSparc Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • SciSparc Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Wilk Technologies Ltd
  • Rafa Laboratories Co Ltd
  • BiondVax Pharmaceuticals Ltd
  • Neopharm Ltd
  • Compugen Ltd